Clinical trial
Dose Ranging Study of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects…
NCT00436683 · Ineos Healthcare Limited, Industry · Completed
Key facts
| NCT number | NCT00436683 |
|---|---|
| Title | Dose Ranging Study of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia |
| Official title | An Open Label, Dose-Ranging Study to Establish the Tolerability of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia. |
| Acronym | ACT3 |
| Lead sponsor | Ineos Healthcare Limited, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Kidney Failure |
| Intervention type | Drug |
| Interventions | Fermagate, Sevelamer HCl |
| Enrollment | 64 |
| Start date | Feb 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Feb 19, 2007 |
| Last update posted | Aug 10, 2009 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: